Literature DB >> 11888351

Hypotonic-hyporesponsive episodes following pertussis vaccination: a cause for concern?

Michael S Gold1.   

Abstract

Vaccine safety has become a major community concern and of particular importance for parents, vaccine recipients and vaccine providers. A hypotonic-hyporesponsive episode (HHE) is a sudden and unexpected episode of loss of tone, unresponsiveness and colour change which uncommonly affects infants and children after vaccination. Although any vaccine may be associated with this adverse event, HHE usually follows administration of a pertussis containing vaccine. There has been renewed interest in this adverse event in the light of community concerns regarding vaccine safety. The focus of this interest has been to formulate an acceptable case definition, to document possible risk factors and to better define the outcome of HHE. In addition, studies have documented the outcome of revaccination of children who have had an HHE. Although much remains to be learnt about HHE it would appear that there are no long-term sequelae and that children who have had an HHE can be revaccinated. Parents should be provided with the available information such that they can make an assessment of the risks and benefits of pertussis vaccination. The benefits of pertussis vaccination still outweigh the risk and universal childhood pertussis vaccination should continue to be advocated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11888351     DOI: 10.2165/00002018-200225020-00003

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  26 in total

1.  A comparison of serious adverse reactions to whole cell and acellular pertussis vaccines in South Australia.

Authors:  M Gold; A Kempe; M Osbourn
Journal:  Med J Aust       Date:  1999-09-20       Impact factor: 7.738

2.  Impact of anti-vaccine movements on pertussis control: the untold story.

Authors:  E J Gangarosa; A M Galazka; C R Wolfe; L M Phillips; R E Gangarosa; E Miller; R T Chen
Journal:  Lancet       Date:  1998-01-31       Impact factor: 79.321

3.  The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment.

Authors:  S Rosenthal; R Chen; S Hadler
Journal:  Arch Pediatr Adolesc Med       Date:  1996-05

4.  Collapse reactions after whole cell pertussis vaccination.

Authors:  E Miller
Journal:  BMJ       Date:  1998-03-21

5.  Rate of recurrent collapse after vaccination with whole cell pertussis vaccine: follow up study.

Authors:  P E Vermeer-de Bondt; J Labadie; H C Rümke
Journal:  BMJ       Date:  1998-03-21

6.  Hypotonic hyporesponsive episodes in eight pertussis vaccine studies.

Authors:  H Heijbel; M Ciofi degli Atti; E Harzer; J Liese; M P Preziosi; F Rasmussen; H J Schmitt; J Storsaeter; J Taranger; M Uberall; A E Tozzi
Journal:  Dev Biol Stand       Date:  1997

7.  Further experience of reactions, especially of a cerebral nature, in conjunction with triple vaccination: a study based on vaccinations in Sweden 1959-65.

Authors:  J Ström
Journal:  Br Med J       Date:  1967-11-11

8.  Hypotonic-hyporesponsive episodes reported to the Vaccine Adverse Event Reporting System (VAERS), 1996-1998.

Authors:  T S DuVernoy; M M Braun
Journal:  Pediatrics       Date:  2000-10       Impact factor: 7.124

9.  The Australian College of Paediatrics Policy Statement. Contraindications to immunization against pertussis.

Authors: 
Journal:  J Paediatr Child Health       Date:  1994-08       Impact factor: 1.954

10.  Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children.

Authors:  C L Cody; L J Baraff; J D Cherry; S M Marcy; C R Manclark
Journal:  Pediatrics       Date:  1981-11       Impact factor: 7.124

View more
  3 in total

Review 1.  Pertussis: Microbiology, Disease, Treatment, and Prevention.

Authors:  Paul E Kilgore; Abdulbaset M Salim; Marcus J Zervos; Heinz-Josef Schmitt
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

2.  [Post-licensure safety surveillance for Prevenar 13® in France].

Authors:  M-S Agier; S Marchand; N Paret; S Gautier; A-P Jonville-Béra
Journal:  Arch Pediatr       Date:  2017-02-24       Impact factor: 1.180

Review 3.  Frequently asked questions on seven rare adverse events following immunization.

Authors:  G L D'alò; E Zorzoli; A Capanna; G Gervasi; E Terracciano; L Zaratti; E Franco
Journal:  J Prev Med Hyg       Date:  2017-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.